1. 首页
  2. 产品目录
  3. 天然产物
  4. 二苯乙烯类

Combrestatin A4

Combrestatin A4 （订货以CAS编码或英文名称为准）

Combretastatin A4 是一种 microtubule 抑制剂，能够与 β-tubulin 结合，Kd 值为 0.4 μM。
创赛科技提供的所有产品仅用于科研等非医疗用途，非药品不可食用，不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。如您需要产品COA等资料，可至下方“质量控制”中下载
编号：PC54145
分子式：C22H43NO7
CAS号：117048-59-6
分子量：433.58
储存条件：-20℃
申请试用
货号 品牌 规格 纯度/含量 标准价 优惠价 库存货期 数量 购买
PC54145-100mg Medlife 100mg
≥98%
 待询 登录后可见
PC54145-25mg Medlife EA
≥98%
 ¥3761.00 登录后可见
PC54145-50mg Medlife EA
≥98%
 ¥6659.00 登录后可见
PC54145-10mg Medlife EA
≥98%
 ¥1591.00 登录后可见
PC54145-5mg Medlife EA
¥849.00 登录后可见
中文名称： Azithromycin Impurity 34
中文别名： 康普瑞汀;康布瑞汀;康普立停 A4;(Z)-2-甲氧基-5- (3,4,5-三甲氧基苯乙烯基)苯酚;(Z)-2-甲氧基-5-(3,4,5-三甲氧基苯乙烯)苯酚;(Z)-3, 4, 5,4’,-四甲氧基-3’-羟基二苯乙烯;(Z)-3,4,5,4',-四甲氧基-3'-羟基二苯乙烯;Combretastatin A4 康普立停 A4;Combretastatin A4 抑制剂;康普瑞丁;康普瑞丁A4;康普瑞汀 A4;康普瑞汀 康普瑞丁;康普瑞汀(康布瑞汀);考布他汀A4;3'-羟基-3,4,4',5-四甲氧基-顺-均二苯乙烯;康普瑞汀(CA-4);3'-羟基-3,4,4',5-四甲氧基-顺-芪;考布他丁A4;康普瑞汀标准品;(Z)-2-甲氧基-5-(3,4,5-三甲氧基苯乙烯基)苯酚;康普瑞汀 1G;康普瑞汀A4
英文名称： Combrestatin A4
英文别名： azithromycin aglycone
CAS号： 117048-59-6
分子式： C22H43NO7
分子量： 433.58
详细描述 Combretastatin A4 是一种 microtubule 抑制剂，能够与 β-tubulin 结合，Kd 值为 0.4 μM。
搜索质检报告(COA)
相关产品
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,11,13- pentahydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6- azacyclopentadecan-15-one
N-((2R,3R,4S,6R)-2-(((2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2- ethyl-3,4,10-trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadecan-11-yl)oxy)-3-hydroxy-6-methyl tetrahydro-2H-pyran-4-yl)-N,4-dimethylbenzenesulfonamide
(3R,4S,5S,6R,7R,9R,11S,12R,13S,14R,E)-6-(((2R,3R,4S,6R)- 4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2- yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5- hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl) oxy)-10-(hydroxyimino)-3,5,7,9,11,13-hexamethyl oxacyclotetradecan-2-one
N-((2R,3R,4S,6R)-2-(((2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2- ethyl-3,4,10-trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadecan-11-yl)oxy)-3-hydroxy-6-methyl tetrahydro-2H-pyran-4-yl)-N-methylformamide
N-(4-(N-((2R,3R,4S,6R)-2-(((2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadecan-11-yl)oxy)-3-hydroxy-6-methyltetrahydro-2H-pyran-4-yl)-N-methylsulfamoyl)phenyl)acetamide
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-(((2R,3R,4S,6R)- 4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl) oxy)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl- 1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10- trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6- dimethyltetrahydro-2H-pyran-2-yl)oxy)-11-(((2R,3R,4S,6R)- 3-hydroxy-6-methyl-4-(methylamino)tetrahydro-2H-pyran-2- yl)oxy)-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan- 15-one
(2R,3R,4S,6R)-2-(((2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- 2-ethyl-3,4,10-trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4- methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,6, 8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadecan- 11-yl)oxy)-3-hydroxy-N,N,6-trimethyltetrahydro-2H-pyran-4- amine oxide
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10- trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6- dimethyltetrahydro-2H-pyran-2-yl)oxy)-11-(((2R,3R,4S,6R)- 3-hydroxy-6-methyl-4-(methylamino)tetrahydro-2H-pyran-2- yl)oxy)-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan- 15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,11,13- pentahydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6- azacyclopentadecan-15-one